Home Research For Researchers Research Digest Etiology

New studies focused on genetic, environmental or lifestyle factors that influence risk.


Ambry to Present New Data Showing That up to 30% of Cancer Risk Carriers Are Missed by Current Testing Guidelines at the 2017 ASCO Meeting
ASCO abstract

  • Meeting: 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
  • Institution(s): Beth Israel Deaconess Medical Center, Cambridge, MA, and others
  • Lead author(s): Mary Linton Bounetheau Peters
  • Major finding: Preliminary results show that 6.6% of unselected pancreatic ductal adenocarcinoma (PDAC) patients carry a germline mutation in a gene known to increase PDAC risk and 4.3% have a mutation in genes not previously linked to PDAC. Existing testing criteria did not identify 30% of carriers. Continued refinement of guidelines is necessary to align genetic testing with inherited PDAC risk.


Wage Hope With Us

Join us to make a difference for pancreatic cancer patients.

shop purple logo

Gear, apparel, accessories and more to show off your purple pride.

Shop Now 

©2020 Pancreatic Cancer Action Network. All rights reserved. Terms of Use | Privacy Policy

Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision Promise℠ and Demand Better For Patients. For Survival.℠ are the trademarks of the Pancreatic Cancer Action Network, Inc.

The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.